APOL1 Null Alleles from a Rural Village in India Do Not Correlate with Glomerulosclerosis

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Johnstone, Duncan B ^a,e   Shegokar, Vijay ^b   Nihalani, Deepak ^a   Rathore, Yogendra Singh ^c   Mallik, Leena ^c   Ashish, ^c   Zare, Vasant ^d   Ikizler, H Omer ^a   Powar, Rajaram ^b   Holzman, Lawrence B ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Department of Microbiology   (India)

^c INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

^d Public Health Institute of Nagpur   (India)

^e TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; APOLIPOPROTEINL1 GENE; ARTICLE; CONTROLLED STUDY; FEMALE; FOCAL GLOMERULOSCLEROSIS; GENE CLUSTER; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HOMOZYGOTE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MOLECULAR EVOLUTION; NULL ALLELE; PRIMATE; RECESSIVE INHERITANCE; RODENT; RURAL AREA;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INDIA; MALE; MIDDLE AGED; MUTATION; RISK FACTORS; RURAL POPULATION; YOUNG ADULT;

PRIMATES; RODENTIA; TRYPANOSOMA;

EID: 84871582404     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051546     Document Type: Article

References (52)

1. National Institutes of Health NIoDaDaKD, Bethesda, MD (2011) U S Renal Data System, USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.
2. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, et al. (2008) MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 40: 1185-1192.
3. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, et al. (2008) MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nature genetics 40: 1175-1184.
4. Seri M, Pecci A, Di Bari F, Cusano R, Savino M, et al. (2003) MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine 82: 203-215.
5. Arrondel C, Vodovar N, Knebelmann B, Grunfeld JP, Gubler MC, et al. (2002) Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. Journal of the American Society of Nephrology: JASN 13: 65-74.
6. Behar DM, Rosset S, Tzur S, Selig S, Yudkovsky G, et al. (2010) African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans. Human molecular genetics 19: 1816-1827.
7. Nelson GW, Freedman BI, Bowden DW, Langefeld CD, An P, et al. (2010) Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15. Human molecular genetics 19: 1805-1815.
8. Bostrom MA, Freedman BI, (2010) The spectrum of MYH9-associated nephropathy. Clin J Am Soc Nephrol 5: 1107-1113.
9. Freedman BI, Hicks PJ, Bostrom MA, Comeau ME, Divers J, et al. (2009) Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. Nephrol Dial Transplant 24: 3366-3371.
10. Bostrom MA, Hicks PJ, Lu L, Langefeld CD, Freedman BI, et al. (2010) Association of polymorphisms in the klotho gene with severity of non-diabetic ESRD in African Americans. Nephrol Dial Transplant 25: 3348-3355.
11. Johnstone DB, Zhang J, George B, Leon C, Gachet C, et al. (2011) Podocyte-specific deletion of Myh9 encoding nonmuscle myosin heavy chain 2A predisposes mice to glomerulopathy. Molecular and cellular biology 31: 2162-2170.
12. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, et al. (2010) Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329: 841-845.
13. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, et al. (2010) Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Human genetics 128: 345-350.
14. Freedman BI, Langefeld CD, Lu L, Divers J, Comeau ME, et al. (2011) Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans. PLoS genetics 7: e1002150.
15. Oleksyk TK, Nelson GW, An P, Kopp JB, Winkler CA, (2010) Worldwide distribution of the MYH9 kidney disease susceptibility alleles and haplotypes: evidence of historical selection in Africa. PloS one 5: e11474.
16. Freedman BI, Langefeld CD, (2012) The new era of APOL1-associated glomerulosclerosis. Nephrol Dial Transplant 27: 1288-1291.
17. Cohen DM, Mittalhenkle A, Scott DL, Young CJ, Norman DJ, (2011) African American living-kidney donors should be screened for APOL1 risk alleles. Transplantation 92: 722-725.
18. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, et al. (2009) Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 106: 9362-9367.
19. Duchateau PN, Pullinger CR, Cho MH, Eng C, Kane JP, (2001) Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene. Journal of lipid research 42: 620-630.
20. Page NM, Butlin DJ, Lomthaisong K, Lowry PJ, (2001) The human apolipoprotein L gene cluster: identification, classification, and sites of distribution. Genomics 74: 71-78.
21. Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan DP, Lins L, et al. (2003) Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 422: 83-87.
22. Perez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, Nolan DP, Lins L, et al. (2005) Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 309: 469-472.
23. Smith EE, Malik HS, (2009) The apolipoprotein L family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host-pathogen interactions. Genome research 19: 850-858.
24. Lugli EB, Pouliot M, Portela Mdel P, Loomis MR, Raper J, (2004) Characterization of primate trypanosome lytic factors. Molecular and biochemical parasitology 138: 9-20.
25. Poelvoorde P, Vanhamme L, Van Den Abbeele J, Switzer WM, Pays E, (2004) Distribution of apolipoprotein L-I and trypanosome lytic activity among primate sera. Molecular and biochemical parasitology 134: 155-157.
26. Lecordier L, Vanhollebeke B, Poelvoorde P, Tebabi P, Paturiaux-Hanocq F, et al. (2009) C-terminal mutants of apolipoprotein L-I efficiently kill both Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense. PLoS pathogens 5: e1000685.
27. Wheeler RJ, (2010) The trypanolytic factor-mechanism, impacts and applications. Trends in parasitology 26: 457-464.
28. Vanhollebeke B, Pays E, (2010) The trypanolytic factor of human serum: many ways to enter the parasite, a single way to kill. Molecular microbiology 76: 806-814.
29. Pays E, Vanhollebeke B, (2009) Human innate immunity against African trypanosomes. Current opinion in immunology 21: 493-498.
30. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, et al. (2011) APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. Journal of the American Society of Nephrology: JASN 22: 2129-2137.
31. Friedman DJ, Pollak MR, (2011) Genetics of kidney failure and the evolving story of APOL1. The Journal of clinical investigation 121: 3367-3374.
32. Merino D, Giam M, Hughes PD, Siggs OM, Heger K, et al. (2009) The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like prosurvival proteins. J Cell Biol 186: 355-362.
33. Wan G, Zhaorigetu S, Liu Z, Kaini R, Jiang Z, et al. (2008) Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J Biol Chem 283: 21540-21549.
34. Chaudhary S, Pak JE, Gruswitz F, Sharma V, Stroud RM, (2012) Overexpressing human membrane proteins in stably transfected and clonal human embryonic kidney 293S cells. Nat Protoc 7: 453-466.
35. Madhavan SM, O'Toole JF, Konieczkowski M, Ganesan S, Bruggeman LA, et al. (2011) APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 22: 2119-2128.
36. Papeta N, Kiryluk K, Patel A, Sterken R, Kacak N, et al. (2011) APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol 22: 1991-1996.
37. Greenwald IS, Horvitz HR, (1982) Dominant suppressors of a muscle mutant define an essential gene of Caenorhabditis elegans. Genetics 101: 211-225.
38. Wilkie AO, (1994) The molecular basis of genetic dominance. Journal of medical genetics 31: 89-98.
39. Ashley-Koch AE, Okocha EC, Garrett ME, Soldano K, De Castro LM, et al. (2011) MYH9 and APOL1 are both associated with sickle cell disease nephropathy. British journal of haematology 155: 386-394.
40. Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M, et al. (2011) The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 11: 1025-1030.
41. Johnstone DB, (2011) Mechanism of action of APOL1 in renal allograft survival (and Native CKD) remains unclear. Am J Transplant 11: 2258-2259; author reply 2260.
42. Joshi PP, Shegokar VR, Powar RM, Herder S, Katti R, et al. (2005) Human trypanosomiasis caused by Trypanosoma evansi in India: the first case report. The American journal of tropical medicine and hygiene 73: 491-495.
43. Vanhollebeke B, Truc P, Poelvoorde P, Pays A, Joshi PP, et al. (2006) Human Trypanosoma evansi infection linked to a lack of apolipoprotein L-I. The New England journal of medicine 355: 2752-2756.
44. Chun S, Fay JC, (2011) Evidence for hitchhiking of deleterious mutations within the human genome. PLoS Genet 7: e1002240.
45. Huff CD, Witherspoon DJ, Zhang Y, Gatenbee C, Denson LA, et al. (2012) Crohn's Disease and Genetic Hitchhiking at IBD5. Mol Biol Evol 29: 101-111.
46. Sekine T, Konno M, Sasaki S, Moritani S, Miura T, et al. (2010) Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease. Kidney Int 78: 207-214.
47. Weigel D, Glazebrook J (2008) Genetic analysis of Arabidopsis mutants. CSH protocols 2008: pdb top35.
48. Ailion M, Thomas JH, (2003) Isolation and characterization of high-temperature-induced Dauer formation mutants in Caenorhabditis elegans. Genetics 165: 127-144.
49. Tzur S, Rosset S, Skorecki K, Wasser WG, (2012) APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association- European Renal Association 27: 1498-1505.
50. Kanji Z, Powe CE, Wenger JB, Huang C, Ankers E, et al. (2011) Genetic variation in APOL1 associates with younger age at hemodialysis initiation. Journal of the American Society of Nephrology: JASN 22: 2091-2097.
51. Beales PL, Badano JL, Ross AJ, Ansley SJ, Hoskins BE, et al. (2003) Genetic interaction of BBS1 mutations with alleles at other BBS loci can result in non-Mendelian Bardet-Biedl syndrome. Am J Hum Genet 72: 1187-1199.
52. Hoefele J, Wolf MT, O'Toole JF, Otto EA, Schultheiss U, et al. (2007) Evidence of oligogenic inheritance in nephronophthisis. J Am Soc Nephrol 18: 2789-2795.